eSpOT-ON nuclease is an engineered high-fidelity Cas9 protein designed for therapeutic applications. It offers high on-target editing efficiency while minimizing off-target activity, making it a safer choice for precise cell and gene therapy development. This Cas9 protein is optimized for both accuracy and safety, providing a reliable solution for your gene editing needs.

• Engineered for high on-target efficiency and reduced off-target effects.
• Minimizes off-target edits, enhancing safety in therapeutic applications.
• Produces staggered DNA cuts, which can improve DNA integration.
• Validated for safety and specificity in cell and gene therapies

eSpOT-ON is an engineered high-fidelity Cas9 variant, designed for therapeutic gene editing. Delivered in mRNA format, eSpOT-ON provides superior on-target activity with low off-target effects. This nuclease has been validated in preclinical studies and is ready to support your next breakthrough in cell and gene therapy development.

• Engineered for precise and safe genome editing.
• Significantly reduces off-target editing.
• Lowers the risk of chromosomal translocations.
• Validated in a wide range of human cell lines, including iPSCs.

hfCas12Max is a high-fidelity CRISPR nuclease engineered for therapeutic genome editing. It offers high on-target and low off-target editing across various cell types. Its small size and broad PAM sequence recognition make it an ideal choice for both ex vivo and in vivo CRISPR-based therapeutic development, allowing you to edit more of the genome with confidence.

• Engineered for high-fidelity with high on-target and low off-target editing.
• Broad PAM sequence recognition expands the range of editable genomic sites.
• Small size allows for efficient delivery using AAV and lipid nanoparticles.
• Requires a shorter sgRNA, enhancing stability and editing efficiency.

AccuBase™ is an engineered cytosine base editor designed for therapeutic applications. It enables precise single-base conversions from C to T, minimizing off-target activity and eliminating the risk of double-strand breaks. This makes it a safer and more reliable solution for advancing clinical and commercial applications in cell and gene therapy.

• Engineered for high-efficiency and exceptional fidelity.
• Eliminates double-strand breaks, reducing genomic instability.
• Demonstrates remarkably low off-target activity for safer therapeutics.
• Activates only when bound to the DNA target site, preventing unintended edits.

SpCas9 nuclease is a high-quality, recombinant protein that enables robust and reliable genome editing. This widely used CRISPR nuclease, complexed with a synthetic single guide RNA (sgRNA), can achieve high editing efficiencies. It features two nuclear localization signals (2NLS) to enhance its transport into the nucleus for precise gene editing.

Enables high-precision gene editing with a blunt-end cut.

Features two nuclear localization signals (2NLS) for enhanced nuclear transport.

Complexed with sgRNA to achieve high editing efficiencies.

Used in a wide range of applications, including cell and gene therapy.

hfCas12Max is a high-fidelity CRISPR nuclease engineered for therapeutic genome editing. It offers high on-target and low off-target editing across various cell types. Its small size and broad PAM sequence recognition make it an ideal choice for both ex vivo and in vivo CRISPR-based therapeutic development, allowing you to edit more of the genome with confidence.

• Engineered for high-fidelity with high on-target and low off-target editing.
• Broad PAM sequence recognition expands the range of editable genomic sites.
• Small size allows for efficient delivery using AAV and lipid nanoparticles.
• Requires a shorter sgRNA, enhancing stability and editing efficiency.

SpCas9 nuclease is a high-quality, recombinant protein that enables robust and reliable genome editing. This widely used CRISPR nuclease, complexed with a synthetic single guide RNA (sgRNA), can achieve high editing efficiencies. It features two nuclear localization signals (2NLS) to enhance its transport into the nucleus for precise gene editing.

• Enables high-precision gene editing with a blunt-end cut
• Features two nuclear localization signals (2NLS) for enhanced nuclear transport
• Complexed with sgRNA to achieve high editing efficiencies
• Used in a wide range of applications, including cell and gene therapy

AccuBase™ is an engineered cytosine base editor designed for therapeutic applications. It enables precise single-base conversions from C to T, minimizing off-target activity and eliminating the risk of double-strand breaks. This makes it a safer and more reliable solution for advancing clinical and commercial applications in cell and gene therapy.

• Engineered for high-efficiency and exceptional fidelity.
• Eliminates double-strand breaks, reducing genomic instability.
• Demonstrates remarkably low off-target activity for safer therapeutics.
• Activates only when bound to the DNA target site, preventing unintended edits.

eSpOT-ON is an engineered high-fidelity Cas9 variant, designed for therapeutic gene editing. Delivered in mRNA format, eSpOT-ON provides superior on-target activity with low off-target effects. This nuclease has been validated in preclinical studies and is ready to support your next breakthrough in cell and gene therapy development.

• Engineered for precise and safe genome editing.
• Significantly reduces off-target editing.
• Lowers the risk of chromosomal translocations.
• Validated in a wide range of human cell lines, including iPSCs.

eSpOT-ON nuclease is an engineered high-fidelity Cas9 protein designed for therapeutic applications. It offers high on-target editing efficiency while minimizing off-target activity, making it a safer choice for precise cell and gene therapy development. This Cas9 protein is optimized for both accuracy and safety, providing a reliable solution for your gene editing needs.

• Engineered for high on-target efficiency and reduced off-target effects.
• Minimizes off-target edits, enhancing safety in therapeutic applications.
• Produces staggered DNA cuts, which can improve DNA integration.
• Validated for safety and specificity in cell and gene therapies